EHA 2023 | Phase I/II BRUIN update: efficacy of pirtobrutinib in R/R Waldenström’s macroglobulinemia

I’m very excited about this, this non-covalent BTK inhibitor that has been recently approved in the US for the treatment of Mantle cell lymphoma, but in the original BRUIN study also patients with other lymphoproliferative disorders were enrolled. And Waldenström Macroglobulinemia is a rare disease and patients relapsing after covalent BTK inhibitor are for sure an unmet need in this field. So around 70 patients with Waldenström Macroglobulinemia were enrolled in the BRUIN study. Basically, 80% of them were previously exposed to covalent BTK inhibitor and pirtobrutinib was able to achieve a very high overall response rate in 70% of them and in the whole cohort was very well tolerated, meaning that we had very few adverse events. Only 2.5% of patients, among more than 700 patients, interrupting treatment, discontinuing treatment because of tolerability issue, and, in the vast majority, they could continue treatment at the standard dose while on study. So it’s a very powerful drug that I hope can become available for many other lymphoproliferative disorders soon.